Compare · EW vs INGN
EW vs INGN
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Inogen Inc (INGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and INGN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $48.42B, about 253.9x INGN ($190.7M).
- INGN has been more active in the news (7 items in the past 4 weeks vs 6 for EW).
- EW has more recent analyst coverage (25 ratings vs 11 for INGN).
- Company
- Edwards Lifesciences Corporation
- Inogen Inc
- Price
- -
- -
- Market cap
- $48.42B
- $190.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 6
- 7
- Recent ratings
- 25
- 11
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Latest EW
- Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
Latest INGN
- SEC Form DEF 14A filed by Inogen Inc
- Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form PRE 14A filed by Inogen Inc
- SEC Form 4 filed by Richardson Jason Andrew
- SEC Form 3 filed by new insider Richardson Jason Andrew
- Inogen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Inogen Announces the Appointment of Vafa Jamali to Board of Directors
- Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
- Inogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)